18F-FDG PET and PET/CT in the Evaluation of Cancer Treatment Response

被引:233
作者
Ben-Haim, Simona [1 ]
Ell, Peter [1 ]
机构
[1] UCL, Inst Nucl Med, London, England
关键词
F-18-FDG; PET; PET/CT; tumor response; treatment monitoring; outcome; POSITRON-EMISSION-TOMOGRAPHY; NON-HODGKINS-LYMPHOMA; CELL LUNG-CANCER; PRIMARY BREAST-CANCER; FDG-PET; THERAPY RESPONSE; PROGNOSTIC VALUE; RECTAL-CANCER; NEOADJUVANT CHEMOTHERAPY; PATHOLOGICAL RESPONSE;
D O I
10.2967/jnumed.108.054205
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Multimodality imaging, as represented by its greatest exponent, PET/CT, has a firm place in the evaluation of a patient presenting with cancer. With F-18-FDG, PET/CT is rapidly becoming the key investigative tool for the staging and assessment of cancer recurrence. In the last 5 y, PET/CT has also gained widespread acceptance as a key tool used to demonstrate early response to intervention and therapy. In this setting, a major clinical need is being addressed with F-18-FDG PET/CT, because of its inherent ability to demonstrate (before other markers of response) if disease modification has occurred. This review presents available evidence to this effect.
引用
收藏
页码:88 / 99
页数:12
相关论文
共 81 条
[1]   Response prediction by FDG-PET after neoadjuvant radiochemotherapy and combined regional hyperthermia of rectal cancer:: correlation with endorectal ultrasound and histopathology [J].
Amthauer, H ;
Denecke, T ;
Rau, B ;
Hildebrandt, B ;
Hünerbein, M ;
Ruf, J ;
Schneider, U ;
Gutberlet, M ;
Schlag, PM ;
Felix, R ;
Wust, P .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2004, 31 (06) :811-819
[2]  
Antoch G, 2004, J NUCL MED, V45, P357
[3]   The changing classification of non-Hodgkin's lymphomas [J].
Armitage, JO .
CA-A CANCER JOURNAL FOR CLINICIANS, 1997, 47 (06) :323-&
[4]  
Aspinall MG, 2007, HARVARD BUS REV, V85, P108
[5]   Prediction of response to neoadjuvant chemotherapy by sequential F-18-fluorodeoxyglucose positron emission tomography in patients with advanced-stage ovarian cancer [J].
Avril, N ;
Sassen, S ;
Schmalfeldt, B ;
Naehrig, J ;
Rutke, S ;
Weber, WA ;
Werner, M ;
Graeff, H ;
Schwaiger, M ;
Kuhn, W .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (30) :7445-7453
[6]   F-18 fluorodeoxyglucose-positron emission tomography imaging for primary breast cancer and loco-regional staging [J].
Avril, Norbert ;
Adler, Lee P. .
RADIOLOGIC CLINICS OF NORTH AMERICA, 2007, 45 (04) :645-+
[7]   We should desist using RECIST, at least in GIST [J].
Benjamin, Robert S. ;
Choi, Haesun ;
Macapinlac, Homer A. ;
Burgess, Michael A. ;
Patel, Shreyaskumar R. ;
Chen, Lei L. ;
Podoloff, Donald A. ;
Charnsangavej, Chuslip .
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (13) :1760-1764
[8]   Treatment monitoring by 18F-FDG PET/CT in patients with sarcomas:: Interobserver variability of quantitative parameters in treatment-induced changes in histopathologically responding and nonresponding tumors [J].
Benz, Matthias R. ;
Evilevitch, Vladimir ;
Allen-Auerbach, Martin S. ;
Eilber, Fritz C. ;
Phelps, Michael E. ;
Czernin, Johannes ;
Weber, Wolfgang A. .
JOURNAL OF NUCLEAR MEDICINE, 2008, 49 (07) :1038-1046
[9]   [18F]FDG-PET predicts complete pathological response of breast cancer to neoadjuvant chemotherapy [J].
Berriolo-Riedinger, Alina ;
Touzery, Claude ;
Riedinger, Jean-Marc ;
Toubeau, Michel ;
Coudert, Bruno ;
Arnould, Laurent ;
Boichot, Christophe ;
Cochet, Alexandre ;
Fumoleau, Pierre ;
Brunotte, Francois .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2007, 34 (12) :1915-1924
[10]   FDG-PET in monitoring therapy of breast cancer [J].
Biersack, HJ ;
Bender, H ;
Palmedo, H .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2004, 31 (Suppl 1) :S112-S117